Eric Bihler, DO
Critical Care Medicine · Pittsburgh, PANPI 1336316793
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.5%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Insmed, Inc. accounts for 98.7% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $10,201 and has fallen 62.5% since, to $3,824 in 2023. Among critical care medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 48 payments — averaging $449.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$21K
- AstraZeneca$193
- Mylan Specialty L.p.$35
- Vapotherm Inc$19
- Amgen$16
- Boehringer Ingelheim$15
- plus $13 from 1 others
What the payments were for
- Consulting fees$10,05047%
- Speaking & faculty fees$9,09542%
- Travel & lodging$1,0335%
- Food & beverage$1,3066%
- Education$1121%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 34 | $21,305 |
| AstraZeneca | 8 | $193 |
| Mylan Specialty L.p. | 2 | $35 |
| Vapotherm Inc | 1 | $19 |
| Amgen | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Arikayce$19,022
How this compares
$21,595 in reported general payments places this provider in the 95th percentile of 354 critical care medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 553 | $404,328 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 15 | $228,987 |
| Breo ElliptaFluticasone/Vilanterol | 140 | $61,085 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 71 | $56,885 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 62 | $44,062 |
| EliquisApixaban | 29 | $34,214 |
| Spiriva RespimatTiotropium Bromide | 33 | $17,289 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 126 | $15,308 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $14,674 |
| SymbicortBudesonide/Formoterol Fumarate | 46 | $14,242 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 49 | $12,717 |
| XareltoRivaroxaban | 23 | $12,473 |
| Atrovent HfaIpratropium Bromide | 17 | $8,318 |
| Roflumilast | 77 | $7,170 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 280 | $7,126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Insmed, Inc.Arikayce | $21,305 | $228,98715 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $193 | $71,127117 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $15 | $31,96359 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 354 critical care medicine providers in Pennsylvania.
Other critical care medicine in Pittsburgh
- Briana DisilvioPittsburgh$204K
- Meilin YoungPittsburgh$182K
- Kees PoldermanPittsburgh$85K
- Michael RisbanoPittsburgh$34K
- Raghavan MuruganPittsburgh$33K
- Tiffany DumontPittsburgh$21K
- Amy SchmetzerPittsburgh$13K
- Stephanie BaltajiPittsburgh$10K
- Billie BarkerPittsburgh$10K
- Douglas WhitePittsburgh$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.